Bodycote plc (BOY.L) Bundle
Start here: Bodycote plc's early‑2025 report packs a mix of resilience and pressure that every investor should parse-group revenue of £246 million in the first four months (an organic decline of 6% versus 2024) yet management holding full‑year revenue guidance at £718 million; profitability showing strain with adjusted operating profit of £55.1 million (down 17.5% H1) despite a stronger adjusted operating margin of 17.9% in 2024 and industry‑leading cash generation of £115.5 million (90% conversion); a conservative balance sheet featuring net debt of £90.2 million (net debt/adjusted EBITDA ~0.3x) alongside equity of £668.1 million and total assets of £1,067.4 million; liquidity signals to monitor-current ratio ~0.68, quick ratio ~0.62, cash £19.1 million and net current liabilities £92.7 million-and market sentiment that paints a nuanced picture with the stock at £645.01 (21 Dec 2025) above its 200‑day MA of £582.69 while analysts average a 12‑month target implying upside; read on to unpack how sector dynamics (aerospace/defence recovery vs automotive and energy headwinds), the Optimise programme, share buybacks and analyst moves like RBC's target shift to £7.75 intersect to shape risk, valuation and the path to potential value creation.
Bodycote plc (BOY.L) - Revenue Analysis
Bodycote reported group revenue of £246 million for the first four months of 2025, representing an organic decline of 6% versus the same period in 2024. Management attributed the decrease to a strong prior-year comparator and a c.1% headwind from lower energy surcharges, while maintaining full-year revenue guidance of £718 million, in line with market expectations.- First 4 months 2025 group revenue: £246m (organic -6% vs. 2024)
- Energy surcharge headwind: ~1%
- Full-year revenue guidance: £718m (unchanged)
- Analyst reaction: RBC Capital raised price target to £7.75, citing solid outlook and restructuring progress
| Metric | First 4 months 2025 | Comparator / Note |
|---|---|---|
| Reported group revenue | £246m | Organic -6% vs. first 4 months 2024 |
| Energy surcharge impact | ~1% headwind | Lower surcharges reduced revenue |
| Full-year revenue guidance | £718m | Maintained; aligns with market expectations |
| Analyst price target (RBC) | £7.75 | Raised on solid outlook and restructuring progress |
- Aerospace & defense: resilience noted - civil aerospace supply-chain conditions improving; defense revenue growth, notably in Western Europe.
- Automotive & industrial: faced headwinds, though showing sequential improvement in activity.
- Energy: decline driven by the end of oil & gas project work, weighing on overall revenue.
Bodycote plc (BOY.L) - Profitability Metrics
Key profitability indicators for Bodycote plc (BOY.L) show a mixed picture: operational improvement on an adjusted basis in 2024, strong cash generation, but statutory profits impacted by specific charges and a near-term decline in adjusted operating profit in H1 2025.
- Adjusted operating profit (H1 2025): £55.1m - down 17.5% vs H1 2024.
- Adjusted operating margin (FY 2024): 17.9% - improved from 16.7% in 2023.
- Statutory operating profit (FY 2024): £37.9m - reflects Optimisation programme charges, ERP-related impairment and goodwill impairment.
- Adjusted operating cash flow (FY 2024): £115.5m with a 90% conversion rate.
- Net margin (FY 2024): 8.01%.
- Analyst EPS projection (current fiscal year): ~54.05.
| Metric | Value | Period | Comment |
|---|---|---|---|
| Adjusted Operating Profit | £55.1m | H1 2025 | -17.5% vs H1 2024 |
| Adjusted Operating Margin | 17.9% | FY 2024 | Up from 16.7% in 2023 |
| Statutory Operating Profit | £37.9m | FY 2024 | Includes Optimisation, ERP impairment, goodwill impairment |
| Adjusted Operating Cash Flow | £115.5m | FY 2024 | 90% cash conversion |
| Net Margin | 8.01% | FY 2024 | Profitability after tax and non‑operating items |
| Analyst EPS (est.) | ~54.05 | Current fiscal year | Market consensus projection |
- Drivers of adjusted margin improvement: pricing, cost control and operational efficiency initiatives contributing to 17.9% in FY 2024.
- Headwinds to profitability: one-off charges (Optimisation programme, ERP and goodwill impairments) weighing on statutory results in FY 2024.
- Cash profile: strong conversion (90%) and £115.5m adjusted operating cash flow supporting reinvestment and balance sheet flexibility.
For background on the company's structure, history and strategy that contextualise these metrics, see Bodycote plc: History, Ownership, Mission, How It Works & Makes Money
Bodycote plc (BOY.L) - Debt vs. Equity Structure
Bodycote's balance-sheet posture through 2024-2025 shows a conservative leverage profile alongside active capital returns to shareholders.- Net debt (ex‑lease liabilities): £90.2m as of 30 Apr 2025 (£68.3m at 31 Dec 2024).
- Change driver: £30m share buyback program launched Jan 2025.
- Net debt / adjusted EBITDA: ~0.3x (indicative of low leverage and capacity to absorb volatility).
- Equity attributable to owners: £668.1m at 31 Dec 2024 (down from £790.8m in 2023 - impacts included impairments and buybacks).
- Capital redemption reserve: £131.3m in 2024 (from £129.8m in 2023), supporting a stable equity base.
- Total assets / total liabilities (31 Dec 2024): £1,067.4m / £397.5m.
| Metric | 31 Dec 2023 | 31 Dec 2024 | 30 Apr 2025 |
|---|---|---|---|
| Net debt (ex leases) | - | £68.3m | £90.2m |
| Equity attributable to owners | £790.8m | £668.1m | - |
| Capital redemption reserve | £129.8m | £131.3m | - |
| Total assets | - | £1,067.4m | - |
| Total liabilities | - | £397.5m | - |
| Net debt / adjusted EBITDA (approx) | - | ~0.3x | ~0.3x |
Bodycote plc (BOY.L) - Liquidity and Solvency
Key short‑term and long‑term financial indicators for Bodycote plc as of 31 December 2024 point to mixed liquidity pressures alongside strong solvency metrics. The following data summarize the most relevant figures and their immediate implications for operational flexibility and capital structure.
| Metric | Value | Interpretation |
|---|---|---|
| Current ratio (Current assets / Current liabilities) | 0.68 | Below 1.0 - potential short‑term liquidity constraint |
| Quick ratio (Excluding inventories) | 0.62 | Limited immediate liquidity without relying on inventory |
| Cash and bank balances | £19.1m | Available buffer for immediate operational needs |
| Net current liabilities | £92.7m | Negative working capital position |
| Net debt / Adjusted EBITDA | 0.3x | Low leverage - strong solvency |
| Debt to equity ratio | 0.13 | Conservative financing, low financial risk |
- Short‑term liquidity: Current ratio of 0.68 and quick ratio of 0.62 indicate working capital pressure and limited ability to cover short‑term obligations from liquid assets.
- Cash buffer: £19.1m in cash helps meet near‑term needs but may be insufficient if receivables collection or inventory turns deteriorate.
- Negative working capital: Net current liabilities of £92.7m suggest reliance on non‑current financing or operational cash flow to fund day‑to‑day operations.
Despite the liquidity signals, solvency measures paint a stronger picture:
- Low leverage: Net debt to adjusted EBITDA at 0.3x indicates ample capacity to service debt and absorb shocks to earnings.
- Conservative capital structure: Debt‑to‑equity of 0.13 reflects limited reliance on external debt financing, reducing insolvency risk.
For further context on the company's broader strategy, history and how it generates cash, see: Bodycote plc: History, Ownership, Mission, How It Works & Makes Money
Bodycote plc (BOY.L) - Valuation Analysis
Bodycote's market pricing and analyst inputs in late 2025 point to a stock trading with momentum but mixed external expectations. The share price of £645.01 (21 Dec 2025) sits above the 200-day moving average of £582.69, signaling positive market sentiment and recent strength.- Market price (21 Dec 2025): £645.01
- 200-day moving average: £582.69
- Analyst consensus: Moderate Buy - average 12-month price target £10.35 (implying ~16.46% upside)
- RBC Capital: price target raised to £7.75 (cites solid outlook and restructuring progress)
- JPMorgan Chase & Co.: Neutral, price target £670
| Metric | Value |
|---|---|
| Spot share price (21 Dec 2025) | £645.01 |
| 200-day MA | £582.69 |
| Consensus 12‑mo target (avg) | £10.35 |
| RBC price target | £7.75 |
| JPMorgan price target | £670 |
| Estimated 2025 P/E | 14x |
| Dividend yield | Provided via ongoing programme (see note below) |
| Share buyback | Active - supports shareholder returns |
- Valuation takeaway: market momentum + below-peer P/E = attractive entry for value/earnings-focused investors
- Risk/offset: divergent analyst targets and a range of street views (Moderate Buy vs Neutral) introduce target-driven volatility
Bodycote plc (BOY.L) - Risk Factors
- Sector concentration: Exposure to automotive and industrial end-markets remains significant; these markets continue to show difficult conditions despite sequential improvement.
- Energy revenue decline: The cessation of oil & gas project work has reduced energy-related revenues and contributed to lower overall top-line growth.
- Aerospace supply-chain: Temporary supply-chain disruptions have depressed near-term aerospace performance, though supplier lead-times and delivery metrics are improving.
- Currency translation headwind: Expected full-year currency translation headwind to revenue of approximately £14.0m, introducing FX volatility risk to reported results.
- Working capital / liquidity: A net current liabilities position exists, indicating potential short-term liquidity constraints and reduced operational flexibility.
- Leverage impact from buybacks: Debt levels remain low by peer standards but have risen due to the share buyback programme, modestly reducing financial flexibility.
| Risk | Key Metric / Indicator | Magnitude / Status |
|---|---|---|
| Automotive & Industrial demand | Order intake & revenue growth | Demand subdued; sequential improvement observed |
| Energy segment | Revenue contribution | Declined following end of oil & gas project work |
| Aerospace supply chain | Production lead-times, temporary disruptions | Performance impacted but improving |
| Currency translation | Full-year revenue headwind | ≈ £14.0m |
| Liquidity | Net current liabilities | Net current liabilities position present - potential short-term concern |
| Debt & capital allocation | Net debt / buybacks | Debt increased post-buyback; remains relatively low |
- Operational sensitivity: Margin outcomes are sensitive to volume swings in aerospace and automotive, and to raw‑material and energy cost volatility.
- FX & reporting: A stronger sterling or weaker dollar/euro flow-through will be a recurring headwind relative to prior-year reported comparisons.
- Balance-sheet risk: Net current liabilities may necessitate careful working-capital management; any further share buybacks or M&A could pressure liquidity or increase leverage.
Bodycote plc (BOY.L) - Growth Opportunities
Bodycote's positioning across aerospace, defence and specialist industrial markets underpins a set of clear growth levers for investors, driven by improving end‑market dynamics, margin expansion initiatives and shareholder‑return actions.- Aerospace & Defence tailwinds: improved supply‑chain conditions and continued defence spending in Western Europe support upgraded aftermarket and MRO demand.
- Specialist Technologies momentum: new contracts in defence and oil & gas are expanding exposure to higher‑margin thermal‑processing and surface‑engineering services.
- Optimise programme: targeted to deliver at least £15 million of run‑rate profit benefits by mid‑2027, focusing on footprint rationalisation, pricing discipline and productivity gains.
- Capital allocation: a combination of a share buyback programme and a progressive dividend provides direct mechanisms to enhance shareholder value.
Key quantitative indicators that investors should monitor include programme delivery metrics (realised run‑rate savings vs the £15m target), margin recovery in Specialist Technologies and aerospace, and capital‑return execution (buybacks and dividends).
| Metric | Latest figure / target | Investor implication |
|---|---|---|
| Optimise run‑rate savings | At least £15.0m by mid‑2027 | Direct uplift to operating profit and margins if achieved |
| Analyst 12‑month consensus upside | +16.46% (average price target) | Market expects material share‑price appreciation vs current level |
| Dividend yield | ~2.4% (recent yield range) | Income component of total shareholder return |
| Share buyback | Ongoing programme (company announced repurchases) | Supports EPS and signals capital‑allocation confidence |
| High‑margin contract wins | New Specialist Technologies wins in defence & oil & gas (ongoing) | Improves revenue mix and margin profile |
- Operational focus: cost control, pricing recovery and footprint optimisation under Optimise should lift adjusted operating margins over the medium term.
- Market recovery sensitivity: a rebound in aerospace MRO activity and stable defence budgets in Western Europe are key demand drivers; a sustained supply‑chain normalisation would amplify revenue growth.
- Valuation catalyst: with an average analyst upside of ~16.46% and active buybacks/dividends, the equity case combines earnings‑recovery upside with shareholder‑return mechanics.
For background on the company's evolution and strategic priorities, see: Bodycote plc: History, Ownership, Mission, How It Works & Makes Money
Bodycote plc (BOY.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.